neuromuscular blockade

Atracurium besylate (51W89) is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.

Metocurine is a muscle relaxant through neuromuscular blockade. It is excreted entirely through the kidneys and therefore should not be used in patients with kidney failure.

Fazadinium bromide is a muscle relaxant. It acts as a nicotinic acetylcholine receptor antagonist through the neuromuscular blockade.

RX 67668 is a muscle relaxant used to relieve skeletal muscle fatigue. RX 67668 is an effective cholinesterase inhibitor (IC50: 5 μM for both acetylcholinesterase and butyrylcholinesterase). RX 67668 can reverse the neuromuscular blockade induced by D-tub

Sugammadex is an agent for reversal of neuromuscular blockade by the agent rocuronium in general anaesthesia. It is the first selective relaxant binding agent (SRBA). Sugammadex is a modified γ-cyclodextrin, with a lipophilic core and a hydrophilic periph

Atracurium (BW-33A free acid) is a potent, competitive, non-depolarizing neuromuscular blocking agent and AChR receptor antagonist that induces bronchoconstriction and neuromuscular blockade, while also promoting astroglial differentiation [1] [2] [3] [4] [5].